title: Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation.
abstract: Immunotherapy with interleukin-2 (IL-2) early after peripheral blood stem cell transplantation (PBSCT) is being considered as a potential way to eradicate minimal residual disease. The aim of this study was to determine whether lymphocytes which can acquire lymphokine-activated killer (LAK) cell activity are present in PBSC and in the blood of patients after PBSCT. Fresh and cryopreserved G-CSF-mobilized PBSC from eight patients were incubated with IL-2 (1000 U/ml) for 3-6 days and then tested for LAK activity as measured by lysis of the Daudi cell line. LAK activity was present in both fresh and cryopreserved PBSC, with mean lysis of 32% and 36%, respectively, at an effector:target (E:T) ratio of 50:1. To assess the reconstitution of LAK precursor activity after PBSCT, peripheral blood (PB) obtained from eight other patients 15-60 days after PBSCT was similarly tested. LAK activity was detected in PB from every patient (mean lysis of 38% at an E:T ratio of 12.5:1). PB from patients after PBSCT contained a higher percentage of CD8+ cells and CD56+ cells than did PB from 9 normal controls (47.2% vs. 21.4% CD8+ cells, P < 0.005 and 28.6% vs. 8.6% CD56+ cells, P < 0.0005). Moreover, PB from 4 of 5 patients tested after PBSCT exhibited a high percentage of cells expressing p75, the intermediate affinity IL-2R. Thus, precursor cells capable of acquiring IL-2-inducible LAK activity are present in PBSC and are rapidly reconstituted after PBSCT. The findings provide a rationale for testing IL-2 as a way of decreasing relapses after PBSCT.
authors.affiliation: Division of Oncology, University of Washington, Seattle 98195.
authors.forename: M A
authors.initials: MA
authors.lastname: Neubauer
authors.forename: M C
authors.initials: MC
authors.lastname: Benyunes
authors.forename: J A
authors.initials: JA
authors.lastname: Thompson
authors.forename: W I
authors.initials: WI
authors.lastname: Bensinger
authors.forename: C G
authors.initials: CG
authors.lastname: Lindgren
authors.forename: C D
authors.initials: CD
authors.lastname: Buckner
authors.forename: A
authors.initials: A
authors.lastname: Fefer
mesh_terms: D000328:Adult; D001773:Blood Cells / Q000166:cytology* / Q000276:immunology; D001781:Blood Component Removal; D001804:Blood Transfusion, Autologous; D016516:CD4-CD8 Ratio; D015925:Cryopreservation; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000276:immunology; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D015979:Killer Cells, Lymphokine-Activated / Q000166:cytology*; D008875:Middle Aged; D009000:Monocytes / Q000166:cytology / Q000276:immunology; D010641:Phenotype; D013997:Time Factors
chemical_list: D007376:Interleukin-2